Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.62M Buy
274,859
+109,559
+66% +$2.87M 0.91% 51
2026
Q1
$4.12M Hold
165,300
0.73% 66
2025
Q4
$4.12M Buy
165,300
+15,304
+10% +$386K 0.73% 66
2025
Q3
$3.82M Buy
149,996
+33,601
+29% +$829K 1.2% 41
2025
Q2
$2.82M Buy
116,395
+23,629
+25% +$551K 0.98% 49
2025
Q1
$2.35M Buy
92,766
+15,691
+20% +$411K 0.99% 49
2024
Q4
$2.04M Buy
77,075
+3,404
+5% +$92.3K 0.85% 46
2024
Q3
$2.13M Buy
73,671
+3,767
+5% +$110K 1.05% 42
2024
Q2
$1.96M Buy
69,904
+1,541
+2% +$42.4K 0.93% 45
2024
Q1
$1.9M Buy
68,363
+27,064
+66% +$751K 0.92% 51
2023
Q4
$1.19M Buy
+41,299
New +$1.25M 0.75% 53

Other funds holding PFE

KKM Financial's PFE Position: Q2 2026 in Review

KKM Financial increased its Pfizer (PFE) stake by 66% in Q2 2026, buying an estimated $2.87M and bringing the position to 274,859 shares worth $6.62M. The position accounts for 0.91% of the portfolio, ranked #51.

KKM Financial first reported a position in PFE in Q4 2023 and has held it in 11 quarters since. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • KKM Financial held 274,859 shares of Pfizer worth $6.62M as of Q2 2026.
  • KKM Financial bought 109,559 Pfizer shares in Q2 2026, an estimated $2.87M.
  • Pfizer made up 0.91% of KKM Financial's portfolio in Q2 2026, its #51 holding.
  • KKM Financial first reported a position in Pfizer in Q4 2023 and has held it in 11 quarters since.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on KKM Financial's 13F filing for Q2 2026, filed 14 Aug 2026.